A
0.911
0.04 (4.00%)
| 前收盘价格 | 0.876 |
| 收盘价格 | 0.860 |
| 成交量 | 119,634 |
| 平均成交量 (3个月) | 679,954 |
| 市值 | 14,374,032 |
| 价格/销量 (P/S) | 19.05 |
| 股市价格/股市净资产 (P/B) | 10.70 |
| 52周波幅 | |
| 利润日期 | 15 May 2025 - 19 May 2025 |
| 营业利益率 (TTM) | -19,313.33% |
| 稀释每股收益 (EPS TTM) | -0.420 |
| 季度收入增长率 (YOY) | -9.20% |
| 总债务/股东权益 (D/E MRQ) | 441.35% |
| 流动比率 (MRQ) | 0.330 |
| 营业现金流 (OCF TTM) | -1.81 M |
| 杠杆自由现金流 (LFCF TTM) | -2.07 M |
| 资产报酬率 (ROA TTM) | -38.38% |
| 股东权益报酬率 (ROE TTM) | -531.91% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ABVC Biopharma, Inc. | - | - |
AIStockmoo 评分
-0.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.13 |
|
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 18.05% |
| 机构持股比例 | 3.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Avantax Planning Partners, Inc. | 31 Dec 2024 | 143,968 |
| Spotlight Asset Group, Inc. | 30 Jun 2024 | 100 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合